Technical University of Munich

DGAP-News: Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021

Retrieved on: 
수요일, 9월 15, 2021

Press Release // September 15, 2021

Key Points: 
  • Press Release // September 15, 2021
    Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug development FYB207.
  • For what is now the 22nd time, the Pharma Trend Image & Innovation Awards, also known in the industry as the Pharma Oscars, were presented in various categories at a celebratory awards ceremony under the patronage of Bavarian Health Minister Klaus Holetschek, MdL.
  • "Receiving the prestigious Pharma Trend Image & Innovation 'Most Innovative Product(R)' Award for Leap Innovations is a great pleasure and encourages us in our innovative COVID-19 drug development.
  • Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of an innovative COVID-19 drug.

Linxon announces Stefan Reisacher as CEO

Retrieved on: 
목요일, 9월 2, 2021

VSTERS, Sweden, Sept. 2, 2021 /PRNewswire/ -- The Linxon Board of Directors is pleased to announce the appointment of Stefan Reisacher as CEO of Linxon to lead the company in a new phase of growth.

Key Points: 
  • VSTERS, Sweden, Sept. 2, 2021 /PRNewswire/ -- The Linxon Board of Directors is pleased to announce the appointment of Stefan Reisacher as CEO of Linxon to lead the company in a new phase of growth.
  • "Stefan has successfully led the company as interim CEO since March 2021.
  • After conducting a comprehensive search of internal and external candidates, the Board has selected Stefan because of his values, leadership style, experience, passion for Linxon and his performance as interim CEO since March 2021.
  • As a team, we have made great strides in a short period of time and are completely focused on growing the business and positioning Linxon as an outstanding partner in our key segments," said Stefan Reisacher, CEO, Linxon.

Linxon announces Stefan Reisacher as CEO

Retrieved on: 
목요일, 9월 2, 2021

VSTERS, Sweden, Sept. 2, 2021 /PRNewswire/ -- The Linxon Board of Directors is pleased to announce the appointment of Stefan Reisacher as CEO of Linxon to lead the company in a new phase of growth.

Key Points: 
  • VSTERS, Sweden, Sept. 2, 2021 /PRNewswire/ -- The Linxon Board of Directors is pleased to announce the appointment of Stefan Reisacher as CEO of Linxon to lead the company in a new phase of growth.
  • "Stefan has successfully led the company as interim CEO since March 2021.
  • After conducting a comprehensive search of internal and external candidates, the Board has selected Stefan because of his values, leadership style, experience, passion for Linxon and his performance as interim CEO since March 2021.
  • As a team, we have made great strides in a short period of time and are completely focused on growing the business and positioning Linxon as an outstanding partner in our key segments," said Stefan Reisacher, CEO, Linxon.

DGAP-News: Endor AG: Successful Annual General Meeting 2021 and subdued sales and earnings development in 1st half of 2021

Retrieved on: 
화요일, 8월 31, 2021

Landshut, August 31, 2021 - Endor AG was confirmed in its growth course by its shareholders at the virtual Annual General Meeting 2021.

Key Points: 
  • Landshut, August 31, 2021 - Endor AG was confirmed in its growth course by its shareholders at the virtual Annual General Meeting 2021.
  • The Endor Group's net income tripled from EUR 4.2 million to EUR 12.4 million in fiscal 2020, thus meeting all forecasts.
  • This development could not be continued entirely in the first half of 2021.
  • In total, sales in the first half of 2021 were down two percent on the previous year at EUR 35.4 million.

NTT Research Hosts Upgrade 2021 Global Research Summit

Retrieved on: 
목요일, 8월 26, 2021

NTT Research, Inc. , a division of NTT (TYO:9432), today announced plans to hold Upgrade 2021 , the NTT Research Summit, as a virtual and in-person event on September 20-21.

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced plans to hold Upgrade 2021 , the NTT Research Summit, as a virtual and in-person event on September 20-21.
  • NTT Research opened its offices in July 2019 as a new Silicon Valley startup to conduct basic research and advance technologies that promote positive change for humankind.
  • NTT Research is part of NTT, a global technology and business solutions provider with an annual R&D budget of $3.6 billion.
  • NTT and the NTT logo are registered trademarks or trademarks of NIPPON TELEGRAPH AND TELEPHONE CORPORATION and/or its affiliates.

DGAP-News: Deutsche Familienversicherung confirms all annual targets for 2021 after 24% growth in the first half-year

Retrieved on: 
목요일, 8월 12, 2021

New cooperation with Volkswagen Bank GmbH, among others

Key Points: 
  • New cooperation with Volkswagen Bank GmbH, among others
    All 2021 annual targets confirmed; new products and expansion of sales mix
    Frankfurt am Main, 12 August 2021 - DFV Deutsche Familienversicherung AG ("DFV", "Deutsche Familienversicherung"), the digital insurance company and a leading InsurTech in Europe, consistently continued its dynamic growth path in the second quarter of 2021.
  • The company is hardly affected by the impact of the COVID 19 crisis due to its digital business model and confirms all annual targets for 2021.
  • While premiums in supplementary health insurance increased by 21.3%, growth in non-life insurance was a pleasing 63.7% in the first half of 2021.
  • Accordingly, the share of property insurance in premiums written increased further from 6.8% to 8.9% in the first half of 2021.

DGAP-News: Formycon reports on the status of FYB207 development

Retrieved on: 
수요일, 8월 11, 2021

Press Release // August 11, 2021

Key Points: 
  • Press Release // August 11, 2021
    Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today provided an update on the development status of its COVID-19 drug FYB207.
  • In summary, these laboratory data demonstrate that FYB207 retains its full antiviral potential even in the rapidly spreading SARS-CoV-2 variants-of-concern.
  • Due to the expansion of preclinical testing, clinical development is expected to start in the first half of 2022.
  • Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 fusion protein.

ViewSonic Partners with German A.M. Architekturmuseum Der TUM to Bring an Immersive Architectural Exhibition "Taiwan Acts!" to the World

Retrieved on: 
목요일, 7월 8, 2021

"The exhibitionfocuses on socially engaged architectural projects of humble origins, which sets it apart from other mainstream-oriented architectural exhibitions."

Key Points: 
  • "The exhibitionfocuses on socially engaged architectural projects of humble origins, which sets it apart from other mainstream-oriented architectural exhibitions."
  • "We always welcome international cooperation," said Dr. Andres Lepik, the Director of A.M. Architekturmuseum Der TUM.
  • exhibition runs at the A.M. Architekturmuseum Der TUM (Munich, Germany) from 8 July to 3 October 2021.
  • ViewSonic and the ViewSonic trademarks are trademarks or registered trademarks of ViewSonic Corporation in the United States and/or other countries.

New University in Georgia Benefits from Penetron Technology

Retrieved on: 
목요일, 7월 8, 2021

KIU collaborates with Technical University of Munich (TUM), a public research university in Munich, Germany with a focus on engineering sciences, natural sciences, and life sciences.

Key Points: 
  • KIU collaborates with Technical University of Munich (TUM), a public research university in Munich, Germany with a focus on engineering sciences, natural sciences, and life sciences.
  • "The KIU will be constructed in three phases, with the first phase now completed," explains Jimsher Shengelia, Director of Penetron Georgia.
  • TMS Construction specified the Penetron System for the University's concrete drinking water reservoirs, which will supply the university campus with potable water.
  • As part of the Penetron System, PENETRON ADMIX was specified for the underground concrete structures and the on-site water wells.

NTT Research Opens Medical and Health Informatics Lab Office in Munich

Retrieved on: 
월요일, 8월 3, 2020

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that it has opened an office in Munich, in support of a joint research agreement it entered with the Technical University of Munich (TUM) in November 2019.

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that it has opened an office in Munich, in support of a joint research agreement it entered with the Technical University of Munich (TUM) in November 2019.
  • The joint research agreement associates the NTT Researchs Medical and Health Informatics (MEI) Lab with the Neuroelectronics Group within TUMs Munich School of BioEngineering.
  • Currently, three labs are housed at NTT Research: the Physics and Informatics (PHI) Lab, the Cryptography and Information Security (CIS) Lab, and the Medical and Health Informatics (MEI) Lab.
  • The Munich School of BioEngineering (MSB) is an interdisciplinary, cross-departmental research center within the Technical University of Munich (TUM).